Scarica l'app Stockscreener
2.05
5.13%
0.10
Dopo l'orario di chiusura:
2.07
0.02
+0.98%
Acrivon Therapeutics Inc Borsa (ACRV) Ultime notizie
Q3 EPS Estimate for Acrivon Therapeutics Raised by Analyst - MarketBeat
HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings - MarketBeat
Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A - Stock Titan
Acrivon Therapeutics: Buy Rating Reaffirmed as Pipeline Progress Supports Attractive Valuation; $19 Price Target Maintained - TipRanks
Acrivon Therapeutics, Inc. (ACRV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Acrivon Therapeutics Q2 2026: Net loss narrows to $18.0M, cash at $90.0M - scanx.trade
Acrivon Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Acrivon Therapeutics (NASDAQ:ACRV) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Acrivon Therapeutics Q2 net loss narrows as costs decline - TradingView
BRIEF-Acrivon Therapeutics, Inc Q2 Income From Operations USD -18.668 Million - TradingView
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts - GlobeNewswire
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Acrivon Therapeutics, Inc. expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Acrivon Therapeutics Inc (ACRV) Stock News Today - TradingKey
(ACRV) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Acrivon Therapeutics, Inc. (ACRV) CFO sells 1,142 shares to cover taxes - Stock Titan
Acrivon Therapeutics: Buy Rating Reiterated as ACR-2316’s Emerging Clinical Profile and Differentiated Safety Support Unchanged $19 Price Target - TipRanks
Acrivon advances cancer drug ACR-2316 to dose expansion phase By Investing.com - Investing.com Nigeria
Acrivon advances cancer drug ACR-2316 to dose expansion phase - Investing.com
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Wednesday - MarketBeat
Acrivon Advances ACR-2316, a Potential First-in-Class - GlobeNewswire
Acrivon Therapeutics (ACRV) Holds Near Support as Shares Edge Higher in Quiet SessionGrowth Stock Picks - dars.gov.et
ACRV|Acrivon Therapeutics Inc|Price:1.550|Chg%:+0.050 - TradingKey
Acrivon Therapeutics (ACRV) Dips 1.3% to $1.50 as Biotech Volatility ContinuesGamma Exposure - dars.gov.et
Acrivon Therapeutics (ACRV) Edges Higher as Biotech Stock Tests Key Resistance at $1.63Rounding Top - dars.gov.et
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Down 47.6% in July - MarketBeat
ACRV Stock Price, Quote & Chart - ChartMill
Acrivon Therapeutics Inc (ACRV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acrivon Therapeutics Inc (ACRV) Balance Sheet - TradingKey
ACRV|Acrivon Therapeutics Inc|Price:1.570|Chg%:-0.030 - TradingKey
Acrivon Therapeutics Inc (ACRV) Income Statement - tradingkey.com
TradingKey - TradingKey
Acrivon Therapeutics Inc (ACRV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acrivon Therapeutics Inc (ACRV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acrivon Therapeutics Inc (ACRV) Institutional Confidence - TradingKey
Acrivon Therapeutics Inc (ACRV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acrivon Therapeutics Inc (ACRV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Acrivon Therapeutics Inc (ACRV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACRV|Acrivon Therapeutics Inc|Price:1.730|Chg%:+0.040 - TradingKey
ACRV|Acrivon Therapeutics Inc|Price:1.725|Chg%:-0.015 - TradingKey
Form 4 Acrivon Therapeutics Inc For: 24 July By Investing.com - Investing.com South Africa
Acrivon Therapeutics CLO Mary Miller sells $1,008 in company stock - Investing.com
Acrivon Therapeutics CLO Mary Miller sells $1,008 in company stock By Investing.com - Investing.com Australia
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Insider tax-withholding share sale at Acrivon Therapeutics (NASDAQ: ACRV) - Stock Titan
Acrivon Therapeutics (ACRV) Slips Slightly, Holding Near Key Support ZoneRegression Channel - dars.gov.et
Why Is Acrivon Therapeutics (NASDAQ:ACRV) Fueling Nasdaq Talk? - Kalkine Media
Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference - The Manila Times
Acrivon Therapeutics (ACRV) Holds Steady Near Support Amid Low-Volume TradingVolume Spike Alerts - dars.gov.et
Acrivon highlights AP3 platform and clinical pr... - Pluang
Acrivon to Highlight the Power of its AP3 Platform for - GlobeNewswire
Acrivon Therapeutics (NASDAQ:ACRV) Stock Price Down 0.6%Should You Sell? - MarketBeat
Trading Systems Reacting to (ACRV) Volatility - Stock Traders Daily
Acrivon Therapeutics trades below cash value de... - Pluang
Acrivon Therapeutics: Priced For Failure, Built For Precision (NASDAQ:ACRV) - Seeking Alpha
ACRVAcrivon Therapeutics Inc Options - Finviz
Price to book forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Enterprise value to EBITDA forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Price to sales forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
Price to earnings forward of Acrivon Therapeutics, Inc. – NASDAQ:ACRV - TradingView
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):